Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

In situ gelling drug delivery system

a drug delivery system and gel technology, applied in the direction of biocide, drug composition, nervous disorder, etc., can solve the problems of low low kinetics, and high initial systemic concentration of active agent, and achieve the effect of desirable sustained-release kinetics

Inactive Publication Date: 2011-07-07
PSIVIDA US INC
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This approach provides sustained and localized drug delivery with improved stability and reduced toxicity, maintaining therapeutic concentrations for an extended duration while minimizing systemic exposure and simplifying the preparation process.

Problems solved by technology

There are many useful drugs on the market today for which traditional means of administration are far from ideal.
Bolus injections and oral unit doses typically result in a high initial systemic concentration of the active agent, in excess of the therapeutic concentration, which falls off over time and which will fall below the therapeutic concentration if another bolus is not timely administered.
The result is that the ideal therapeutic concentration is not consistently maintained, there is a risk of toxicity associated with high systemic exposure to the drug, and the maintenance of a minimally effective concentration is dependent upon repeated administration at prescribed intervals.
Patient compliance with a dosing regimen is difficult to ensure, especially where the course of therapy is long or of indeterminate or lifetime duration.
A major disadvantage of the macroscopic devices is their physical size.
Self-administration of such implants is not feasible, and the required intervention of trained medical personnel greatly raises the cost and inconvenience of such treatments.
However, if an aqueous suspension of microspheres is stored for any length of time, the drug will diffuse from the particles into the aqueous phase, furthermore the bioerodable matrix itself is prone to hydrolysis in an aqueous environment.
A second disadvantage is the need for intramuscular injection.
Finally, preparation of the microspheres is a complex process that is not easily carried out reproducibly and reliably, and regulatory validation of the manufacturing process can be a significant obstacle to commercialization of such products.
Such compositions have the disadvantage that they must be carefully protected from premature gelling, through refrigerated storage, and no bioerodable polymer has yet been developed that undergoes a sol-gel transition at about body temperature.
Due to the high water content of the cubic phase, GMO formulations are prone to rapid drug release and are limited in duration of effect to no more than about five days.
There are very few biocompatible liquid crystal compositions that meet the requirement for phase transition to a sufficiently viscous state at physiological conditions.
Rapid solvent escape from the injected composition can lead to rapid and uneven precipitation of the polymer, shrinking of the implant, and local irritation or even necrosis due to exposure of tissues to a high local concentration of solvent.
However, according to these patents, polyethylene glycol is not suitable as a solvent for PLGA.
In situ polymer-precipitation systems solve many of the problems associated with implants, but some difficulties remain.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • In situ gelling drug delivery system
  • In situ gelling drug delivery system
  • In situ gelling drug delivery system

Examples

Experimental program
Comparison scheme
Effect test

example 1

Evaluation of Solubility of PLGA in Organic Solvents

[0073]A sample of PLGA polymer was added to the indicated solvent and rotated overnight at room temperature, and the resulting mixture was examined for undissolved material. The results are shown in Table 1 below.

TABLE 1Solubility of PLGA polymers in selected organic solventsPolymerSolventVisual AppearancePLGA (70:30), 0.2 gPEG 400, 1 mlClear solutionPLGA (70:30), 0.2 gPEG 300, 2 mlClear solutionPLGA (70:30), 0.2 gPEG 200, 2 mlClear solutionPLGA (70:30), 0.1 gDMA, 20 DropsClear solutionPLGA (85:15), 0.1 gPEG 400, 1 mlPartially soluble*PLGA (50:50), 0.1 gPEG 400, 1 mlPartially soluble*PLGA (85:15), 0.1 gDMA, 1 mlClear solutionPLGA (50:50), 0.1 gDMA, 1 mlClear solutionPLGA (90:10), 0.1 gPEG 400, 2 mlPartially soluble*PLGA (70:30), 0.1 gCremophor EL, 2 mlPartially solublePLGA (70:30), 0.1 gCremophor EL-P, 2 mlPartially solublePLGA (70:30), 0.1 gBenzyl alcohol, 0.5 mlClear solutionPLGA (70:30), 0.1 gBenzyl benzoate, 0.5 mlMiscible solu...

example 2

Release Profiles for Morphine-Diclofenac Co-Drug from PLGA (70:30) / PEG Formulations

[0075]Three formulations were evaluated to compare release profiles for morphine-diclofenac co-drug from different concentrations of PLGA (70:30): Formulation A was formulated at about 10 mg / ml morphine-diclofenac co-drug in PLGA (70:30) / PEG 400 solution (−5% (w / v) PLGA in PEG). Formulation B was formulated at about 10 mg / ml morphine-diclofenac co-drug in PLGA (70:30) / PEG 400 solution (˜10% (w / v) PLGA in PEG). Formulation C was formulated at about 10 mg / ml morphine-diclofenac co-drug in PLGA (70:30) / PEG 400 solution (˜20% (w / v) PLGA in PEG).

[0076]Each formulation was loaded into a 1-ml syringe, and 100 μl aliquot was injected into a tube containing 10 ml of 10% plasma in HA (hyaluronic acid) phosphate buffer, pH 7.4. The samples were placed in a water bath at 37° C. for release study. At each time point, the entire release medium was removed and replaced with 10 ml fresh buffer. The removed solution w...

example 3

Release Rate Profile for Morphine-Diclofenac Co-Drug from PLGA (50:50) / PEG Formulation

[0078]The formulation was prepared with 12 mg / ml morphine-diclofenac co-drug in PLGA (50:50) / PEG 400 solution (˜5% (w / v) PLGA in PEG) and loaded into a 1-ml syringe, and 100 μl aliquot was injected into a test tube containing 10 ml of 10% plasma in HA (hyaluronic acid) phosphate buffer, pH 7.4. The samples were placed in a 37° C. water bath. At each time point, the entire release medium was removed and replaced with 10 ml fresh buffer. The removed solutions were analyzed for morphine, diclofenac and the co-drug contents by HPLC.

[0079]The results are shown graphically in FIG. 2. As compared to the results from Example 2, morphine release was much slower in this PLGA (50:50) formulation, even where the PLGA concentration was low as ˜5% (w / v). About 80% of the morphine was released over 40 days. It is most likely that the higher molecular weight of PLGA (50:50) reduces the release rate of morphine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
pharmaceutical compositionaaaaaaaaaa
Login to View More

Abstract

The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 10 / 877,758, filed Jun. 25, 2004, which claims the benefit of U.S. Provisional Application No. 60 / 482,677, filed Jun. 26, 2003, and U.S. Provisional Application No. 60 / 575,307, filed May 28, 2004, the specifications of which are incorporated by reference herein in their entirety.FIELD OF THE INVENTION[0002]The present invention relates to the field of controlled-release and sustained-release drug delivery systems, and particularly to the field of injectable drug delivery implants.BACKGROUND OF THE INVENTION[0003]There are many useful drugs on the market today for which traditional means of administration are far from ideal. Bolus injections and oral unit doses typically result in a high initial systemic concentration of the active agent, in excess of the therapeutic concentration, which falls off over time and which will fall below the therapeutic concentration if another bolus is not tim...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/00A61K31/08A61K31/382A61K31/485A61K31/542A61K47/48
CPCA61K9/0024A61K9/0051A61K9/0092A61K31/382A61K31/485A61K47/48784A61K47/481A61K47/48215A61K9/06A61K31/196A61K47/34A61K31/542A61K47/60A61K47/55A61K47/6903A61P25/04A61P43/00
Inventor SU, DONGLINGASHTON, PAULCHEN, JIANBING
Owner PSIVIDA US INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com